MET D1010N

CI-VAR-00000395Explore in graph →NP_000236.2:p.Asp1010AsnNM_000245.4:c.3028G>ACIViC 1651

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma1
MET D1010N	Crizotinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4780 In a lung adenocarcinoma patient with a MET D1010_splice mutation, a partial response to crizotinib treatment was reported with a 45.1% decrease in tumor measurement by RECIST v1.1. The patient experi… (full text at CIViC) PMID 26791794 · Jorge et al., 2015 · Open in CIViC	civic
Lung Non-Small Cell Carcinoma1
MET D1010N	Crizotinib	Predictive	C	Supports Sensitivity Response	4	submitted	EID6055 A female patient with a lung adenocarcinoma displaying a MET exon 14 donor splice site mutation (D1028N) detected using next generation sequencing. Within 5 weeks of crizotinib therapy, a partial resp… (full text at CIViC) PMID 26892698 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Lung Squamous Cell Carcinoma1
MET D1010N	Crizotinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4781 In a metastatic lung squamous cell carcinoma patient harboring a MET D1010N mutation, MET D1010N mutation was associated with response to crizotinib monotherapy. The patient maintained initial respons… (full text at CIViC) PMID 27022036 · Heist et al., 2016 · Open in CIViC	civic